نتایج جستجو برای: melphalan

تعداد نتایج: 4419  

Journal: Nanomedicine Journal 2019
Elaheh Sadat Mirkamali Goldasteh Zarei Khadijah Kalateh Roya Ahmadi,

Objective (s): The present study aimed to assess the adsorption of fullerene C24 with Melphalan anticancer agent in a solvent phase (water) at the B3LYP/6-31G (d) theoretical level.Materials and Methods: Initially, the structures of Melphalan and fullerene complexes were optimized in four configurations. Afterwards, IR calculations and molecular orbital analysis were performed. In addition, som...

ژورنال: پژوهش در پزشکی 2007
رحیمی, حسین, رضوانی, حمید, عطاریان, حمید, قدیانی, مجتبی,

Primary Plasma cell Leukemia (PCL) is a rare disease with no standard treatment, although, combination chemotherapy, BMT and intermediate dose melphalan have been shown to be effective, in some case reports. Patients usually present with anemia, thrombocytopenia, hypercalcemia, and renal failure. Diagnosis is confirmed by peripheral and bone marrow examination. We recently had a case in our dep...

Journal: :The Journal of pharmacology and experimental therapeutics 1997
Z Y Wu B M Smithers M S Roberts

Melphalan is commonly used as a cytotoxic agent in isolated limb perfusion for locally recurrent malignant melanoma. The time course of melphalan concentrations in perfusate and tissues during a 60-min melphalan perfusion and 30-min drug-free washout in the single-pass perfused rat hindlimb was examined using a physiologically based pharmacokinetic model. The rat hindlimbs were perfused with Kr...

Journal: :Biochemical pharmacology 2004
Joost Rothbarth Cindy Koevoets Rob A E M Tollenaar Mike J Tilby Cornelis J H van de Velde Gerard J Mulder Peter J K Kuppen

Melphalan is a chemotherapeutic drug that exerts its cytotoxic effect mainly through the formation of DNA adducts. We report the specific immunohistochemical detection and visualisation of melphalan-DNA adducts using the monoclonal antibody MP5/73 in cultured tumour cells and solid tumour tissue from colorectal liver metastases from patients treated with melphalan. The human colon cancer cell l...

Journal: :Blood 2002
Victoria J Spanswick Charles Craddock Mallika Sekhar Prem Mahendra Paneesha Shankaranarayana R George Hughes Daniel Hochhauser John A Hartley

Melphalan is widely used as a preparative agent in patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (SCT). Although disease relapse is the major cause of death after a melphalan-conditioned autograft, the mechanism remains unclear. Melphalan produces a number of DNA adducts with the DNA interstrand crosslink (ICL) considered to be the critical cytotoxic lesion...

2018
Holger W. Auner Simona Iacobelli Giulia Sbianchi Cora Knol-Bout Didier Blaise Nigel H. Russell Jane F. Apperley David Pohlreich Paul V. Browne Guido Kobbe Cecilia Isaksson Stig Lenhoff Christof Scheid Cyrille Touzeau Esa Jantunen Achilles Anagnostopoulos Ibrahim Yakoub-Agha Alina Tanase Nicolaas Schaap Wieslaw Wiktor-Jedrzejczak Marta Krejci Stefan O. Schönland Curly Morris Laurent Garderet Nicolaus Kröger

Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine whether melphalan 200 mg/m2 and melphalan 140 mg/m2 are equally effective and tolerable in clinically relevant patient subgroups ...

2013
Susmita Mishra Ravi Prakash Mishra

Melphalan and Mitoxantrone are anthracycline antibiotics used in cancer therapy. This research was carried out to investigate in vitro genotoxic effects of the two (Melphalan and Mitoxantrone) anti-cancer drugs on human lymphocytes using Micronucleus Test. The effect induced by Melphalan was more pronounced than by Mitoxantrone. There was a significant increase in the induction of DNA damage in...

2017
Ryan C. Chai Michelle M. McDonald Rachael L. Terry Nataša Kovačić Jenny M. Down Jessica A. Pettitt Sindhu T. Mohanty Shruti Shah Gholamreza Haffari Jiake Xu Matthew T. Gillespie Michael J. Rogers John T. Price Peter I. Croucher Julian M.W. Quinn

Melphalan is a cytotoxic chemotherapy used to treat patients with multiple myeloma (MM). Bone resorption by osteoclasts, by remodeling the bone surface, can reactivate dormant MM cells held in the endosteal niche to promote tumor development. Dormant MM cells can be reactivated after melphalan treatment; however, it is unclear whether melphalan treatment increases osteoclast formation to modify...

Journal: :Journal of the National Cancer Institute 2004
Flavia Brunstein Saske Hoving Ann L B Seynhaeve Sandra T van Tiel Gunther Guetens Ernst A de Bruijn Alexander M M Eggermont Timo L M ten Hagen

BACKGROUND We have previously shown how tumor response of isolated limb perfusion (ILP) with melphalan was improved when tumor necrosis factor alpha (TNF-alpha) was added. Taking into account that other vasoactive drugs could also improve tumor response to ILP, we evaluated histamine (Hi) as an alternative to TNF-alpha. METHODS We used a rat ILP model to assess the combined effects of Hi and ...

Journal: :The hematology journal : the official journal of the European Haematology Association 2004
Roberto Ria Franca Falzetti Stelvio Ballanti Olivia Minelli Mauro Di Ianni Michele Cimminiello Angelo Vacca Franco Dammacco Massimo F Martelli Antonio Tabilio

INTRODUCTION High-dose chemotherapy conditioning regimens for autologous stem cell transplantation generally give similar results in multiple myeloma. We compared two regimens: melphalan versus melphalan plus busulphan. METHODS In all, 30 untreated patients with stage III low-risk multiple myeloma were studied. After induction with three VAD courses and mobilization with cyclophosphamide 7 g/...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید